HAMPTON, N.J., May 13, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA® (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The ReACT presentation will include final analysis of progression-free survival at 6 months (PFS6) and current data on overall survival and other endpoints. Data contained in the published abstract were from an analysis in October 2014. Data to be presented in the oral session will include comprehensive data from the study through March 2015.
- Abstract #2009: Data from the ReACT study will be presented by David A. Reardon, M.D., in an oral presentation entitled "ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma" on Sunday, May 31, 2015 at 8:00 a.m. CDT. Dr. Reardon, Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Center; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, as well as the lead investigator of the ReACT study, will speak during the Clinical Science Symposium "Immunotherapy for Central Nervous System Tumors: Biomarkers and Novel Data."
- Abstract #TPS1110: The Phase 2b METRIC study will be presented in a clinical trial in progress session as a poster entitled "METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)" on Saturday, May 30, 2015 from 8:00 a.m. to 11:30 a.m.
- Abstract #TPS3105: Data from an investigator-sponsored, Phase 1/2 study of CDX-301, a potent hematopoietic cytokine that stimulates the expansion and differentiation of hematopoietic stem cells and dendritic cells, will be presented as a poster entitled "In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy" on Saturday, May 30, 2015 from 8:00 a.m. to 11:30 a.m.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Company Contact: Sarah Cavanaugh, Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 firstname.lastname@example.org Media Inquiries: Dan Budwick Pure Communications, Inc. (973) 271-6085 email@example.com